Company profile for Sunho Pharmaceutical

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Beijing sunho Pharmaceutical Co., Ltd. always adheres to the corporate culture concept of “Surpassing self and creating development”.Since the company was founded in 2000, it has been relying on its strong R&D advantages, and it has developed into a leading pharmaceutical company driven by production, and pharmaceutical R&D. Sales.The company was successfully listed on the 3rd board of Zhongguancun of the Shenzhen Stock E...
Beijing sunho Pharmaceutical Co., Ltd. always adheres to the corporate culture concept of “Surpassing self and creating development”.Since the company was founded in 2000, it has been relying on its strong R&D advantages, and it has developed into a leading pharmaceutical company driven by production, and pharmaceutical R&D. Sales.The company was successfully listed on the 3rd board of Zhongguancun of the Shenzhen Stock Exchange in August 2007 with a stock code of 430017.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
China
Address
Address
No. 18, Zhonghe Street, Economic and Technological Development Zone, Beijing
Telephone
Telephone
+86 15810113631
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Natural Products Expo

Natural Products Expo

Not Confirmed

envelop Contact Supplier

Natural Products Expo

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/sunho-announces-first-patient-dosed-in-phase-iii-clinical-trial-of-a-potential-first-in-class-immunocytokine-ibb0979-301883084.html

PR NEWSWIRE
21 Jul 2023

https://www.prnewswire.com/news-releases/sunho-announces-first-patient-dosed-in-phase-12-clinical-trial-of-two-first-in-class-immunocytokines-iap0971-and-iae0972-301582075.html

PRNEWSWIRE
07 Jul 2022

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty